Professor Wilbert S. Aronow

Professor of Medicine at New York Medical College Director of Cardiology Research at Westchester Medical Center

Biography

Wilbert S. Aronow MD is Professor of Medicine and Director of Cardiology Research at Westchester Medical Center and New York Medical College Valhalla, NY, USA. Dr. Aronow received his MD from Harvard Medical School. He has edited 21 books and is author or co-author of 1,718 papers,  212 book chapters in 116 books, 960 commentaries, 50 Letters to the Editor, and 1204 abstracts and is presenter or co-presenter of 1,582 talks at meetings. Dr. Aronow is a Fellow of the ACC, the AHA, the ACP, the ACCP, the ASPC, the AGS (Founding Fellow of Western Section), and the GSA. He has been a member of 185 editorial boards of medical journals, editor-in-chief of 5 journals, co-editor of 3 journals, deputy editor of 1 journal, executive editor of 2 journals, associate editor for 9 journals, and  guest editor for 7 other medical journals, and has reviewed manuscripts for 444  journals. He has received each year from 2001-2017 an outstanding teacher and researcher award from the medical residents and  from 2001-2022 from the cardiology fellows at Westchester Medical Center/New York Medical College. He has received awards from the Society of Geriatric Cardiology, the Gerontological Society of America, New York Medical College including the 2014 Chancellor’s Research Award and the 2021 excellence in Teaching Dean’s Faculty Award, the F1000 Faculty Member of the Year Award for the Faculty of Cardiovascular Disorders in 2011, and 2013-2021, the Walter Bleifeld Memorial Award for distinguished contributions to clinical research from the International Academy of Cardiology in July, 2010, a Distinguished Fellowship Award from the International Academy of Cardiology in July, 2012, and the Expertscape World Expert in Hypertension  Award in May, 2019.  He has been a member of 4 national guidelines committees including being a coauthor of the 2010 AMDA guidelines for heart failure , co-chair and first author of the 2011 ACC/AHA expert consensus document on hypertension in the elderly, a coauthor of the 2015 AHA/ACC/ASH scientific statement on treatment of hypertension in patients with coronary artery disease, and a coauthor of the 2017 ACC/AHA  guidelines for the management of patients with hypertension. He was a coauthor of a 2015 position paper from the International Lipid Expert Forum. He was a consultant to the American College of Physicians Information and Educational Resource (PIER) on the module of aortic stenosis, a consultant to the American Board of Internal Medicine on hypertension, a member of the Board of Directors of the ASPC, a member of the ACCP Cardiovascular Medicine and Surgery Network Steering Committee, and is a member of the Scientific Executive Committee of the International Academy of Cardiology. He has been a committee member of other professional societies and a consultant to many government agencies. He has mentored 304 cardiology fellows and 669 other trainees plus numerous junior faculty for publications listed on PubMed during his professional career.

 

Expert content

LBPMC Publications

RSS Aronow WS
  • Long COVID Myocarditis: Incidence, Mechanisms, Clinical Implications, and Management 2026-03-04
    Long coronavirus disease (COVID) (post-acute sequelae of severe acute respiratory syndrome coronavirus 2 infection) is characterized by persistent or new health issues weeks or months after acute COVID-19. Cardiac involvement, including myocarditis, is a notable complication that can occur even after an initially mild infection. To review current literature (2022-2025) on myocarditis in Long COVID, […]
    Anjaneyulu Dunde
  • Lepodisiran: An Updated Review on a Novel and Emerging Lipoprotein (a) Lowering Agent 2026-03-04
    An elevated lipoprotein (a) concentration has been established as an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). There is a high prevalence of elevated lipoprotein (a) in the general population, and given the significant burden of ASCVD, researchers have developed novel therapeutic drugs with a direct lipoprotein (a) reducing effect that are currently under […]
    Manuel Urina-Jassir
  • Post-myocardial infarction complications in patients with inflammatory bowel disease: a retrospective cohort study using the National Inpatient Sample (2016-2022) 2026-03-03
    BACKGROUND: Inflammatory bowel disease (IBD) is associated with systemic inflammation and increased cardiovascular risk, but its impact on in-hospital outcomes after acute myocardial infarction (MI) remains unclear.
    Omar Alkasabrah
  • CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment 2026-02-27
    The obesity epidemic is a major health burden that enhances susceptibility to a broad spectrum of metabolic-associated comorbidities, ranging from fatty liver disease and endocrine dysfunction to traditional risks like type 2 diabetes mellitus and cardiovascular disease. Glucagon-like peptide-1 receptor agonists, including semaglutide, facilitate weight loss alongside glucose metabolism. The dual therapy CagriSema, which combines […]
    Ahmed Farid Gadelmawla
  • VEGF Inhibitors in Hematologic Cancers and Hypertension/Cardiac Effects 2026-02-25
    The therapeutic landscape of hematologic malignancies has undergone a paradigm shift with the increasing incorporation of targeted therapies, including inhibitors of vascular endothelial growth factor (VEGF) signaling. While VEGF-directed agents have historically been developed and deployed in solid tumors, their application in hematologic cancers-particularly multiple myeloma, select leukemias, and rare lymphomas-has expanded in investigational and […]
    Jatin Thukral
  • Oral Anticoagulation Versus No Anticoagulation in Patients of Atrial Fibrillation With Prior History of Intracranial Hemorrhage: A Meta-Analysis 2026-02-20
    Atrial fibrillation is a major cause of ischemic stroke and systemic embolism. Oral anticoagulants (OACs) play a crucial role in preventing thromboembolic events in high-risk patients. However, evidence regarding initiation of OAC in patients with a prior intracranial hemorrhage (ICH) remains limited. We systematically searched PubMed, Scopus, and Cochrane Library for relevant articles published up […]
    Mayank Jha
  • Circulating Tumor DNA and Blood-Based Biomarkers for Predicting Cardiotoxicity in Cancer Therapy: Toward Precision Cardio-Oncology 2026-02-19
    Advances in cancer therapeutics have substantially improved survival across multiple malignancies but have concurrently increased the burden of cancer therapy-related cardiovascular toxicity, establishing cardio-oncology as an essential discipline situated at the interface of oncology and cardiovascular medicine. Despite growing incorporation of cardiac imaging and circulating cardiac biomarkers into surveillance strategies, current approaches remain limited by […]
    Jatin Thukral
  • Emerging and Established Pharmacotherapies for Smoking Cessation: A Review 2026-02-16
    Tobacco use remains the leading preventable cause of death in the United States, with well-established links to cardiovascular morbidity and mortality. Despite the availability of pharmacologic and behavioral therapies, sustained smoking cessation remains a challenge for many individuals. This narrative review evaluates both established and emerging pharmacotherapies for smoking cessation, with a focus on recent […]
    Ellen N Huhulea
  • Left Ventricular Noncompaction Syndrome 2026-02-13
    Left ventricular noncompaction (LVNC) has been classified as a primary cardiomyopathy, predominantly involving the left ventricle, although right ventricular and biventricular involvement have also been reported. The condition may coexist with neuromuscular disorders, congenital cardiac anomalies, and chromosomal abnormalities. Despite its established recognition, LVNC continues to pose a significant challenge, with divergent classifications among major […]
    Kateryna Strubchevska
  • Contemporary Management Strategies for Patent Ductus Arteriosus 2026-02-13
    Patent ductus arteriosus (PDA) is one of the most prevalent congenital cardiac abnormalities. It is more common in preterm newborns and is inversely correlated with gestational age. Whether to treat PDA remains a subject of considerable debate partly attributable to the limited evidence demonstrating long-term benefits of the interventions studied. In the past, surgical ligations […]
    Omar Seyam
  • Differentiation and Management of Intracranial Atherosclerosis-Related Cognitive Impairment From Vascular Dementia 2026-02-13
    Dementia affects more than 6 million individuals in the United States and represents a growing public health challenge. Intracranial atherosclerotic disease (ICAD) is highly prevalent in older adults and is increasingly recognized as an important contributor to cognitive impairment. However, vascular dementia (VaD) is also a major cause of cognitive impairment, and it is often […]
    Kamel Mohamed Al Homsi
  • Advances in the Management of Pediatric Heart Failure: From Medical Therapy to Mechanical Support and Transplantation 2026-02-04
    Pediatric heart failure is a heterogeneous, high-risk clinical syndrome that differs fundamentally from adult heart failure in its etiologies, pathophysiology, and therapeutic responses. Although its absolute prevalence is lower, children experience disproportionate morbidity and mortality, with up to 40% of patients with symptomatic cardiomyopathy progressing to death or transplantation within 2 years of diagnosis. Congenital […]
    Rimsha Ahmad
  • Intracoronary Cryotherapy for Vulnerable Plaque Stabilization 2026-02-03
    Acute coronary syndromes most commonly arise from rupture of biologically vulnerable, rather than hemodynamically severe, coronary plaques. Advances in intravascular and noninvasive imaging techniques, including intravascular ultrasound, optical coherence tomography, near-infrared spectroscopy, and coronary computed tomography angiography, have enabled precise identification of high-risk plaque features such as thin fibrous caps, large lipid cores, and high […]
    Nabel Rajab Basha
  • Obesity-Driven Hypertension: Exploring the Mechanisms and Modern Treatment Strategies 2026-02-02
    Obesity and hypertension are interdependent chronic conditions that substantially elevate global cardiovascular risk. Rising obesity prevalence has led to a parallel increase in hypertension, driven by complex physiological disturbances that extend beyond excess body weight alone. This review synthesizes current evidence on the mechanisms linking adiposity to blood pressure elevation, emphasizing the roles of sympathetic […]
    Ninaad Sindhwani
  • Cardiovascular Complications of Hypoglycemia 2026-02-02
    Hypoglycemia is defined as low blood glucose levels. While it is uncommon in healthy adults, diabetics and other vulnerable patient populations remain at increased risk. The neuroglycopenic symptoms of hypoglycemia, such as dizziness, lethargy, loss of consciousness, etc., are well known. However, hypoglycemia has significant cardiovascular manifestations. During an acute hypoglycemic episode, sympathoadrenal activation causes […]
    Thamid Opi
  • Efficacy and Safety of Apixaban in Cancer-Associated Thromboembolism: A Narrative Review 2026-02-02
    Cancer-associated venous thromboembolism (CA-VTE) is a leading, severe, and potentially life-threatening complication in patients with malignancy. Low-molecular-weight heparin has historically been the standard of care; however, direct oral anticoagulants, particularly direct factor Xa inhibitors, have emerged as effective alternatives. These agents offer the convenience of oral administration, predictable pharmacokinetics, elimination of routine laboratory monitoring, and […]
    Fnu Aperna
  • Cardiovascular Effects of Growth Hormone: From Deficiency to Acromegaly 2026-02-02
    Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) form an endocrine axis with broad cardiovascular relevance because their receptors in cardiomyocytes and vascular cells link hormonal signaling to myocardial growth and performance, vascular tone, endothelial nitric oxide biology, and cardiometabolic risk. This review synthesizes mechanistic, clinical, and epidemiologic evidence to clarify cardiovascular effects across GH/IGF-1 […]
    Negarsadat Neshat
  • Widaplik: A Fixed-Dose Triple Combination for Initial Hypertension Therapy 2026-01-28
    Hypertension remains the leading modifiable risk factor for cardiovascular morbidity and mortality worldwide, yet blood pressure control rates remain suboptimal despite the availability of effective therapies. Contemporary guidelines increasingly recommend early use of combination therapy, recognizing that most patients require multiple agents to achieve target blood pressure. Widaplik, a recently Food and Drug Administration-approved fixed-dose, […]
    Mahnoor Niaz
  • Coronary Microvascular Dysfunction in Cardiovascular Disease: Diagnosis and Management 2026-01-26
    Coronary microvascular dysfunction (CMD) is increasingly recognized as a central mechanism underlying myocardial ischemia, heart failure with preserved ejection fraction, and adverse cardiovascular outcomes in patients with and without obstructive coronary artery disease. The coronary microcirculation plays a critical role in regulating myocardial perfusion through tightly coordinated myogenic, metabolic, and endothelial pathways. Disruption of these […]
    Rimsha Ahmad
  • Beta-adrenergic blockade in survivors of acute myocardial infarction: A half-century of clinical rails and therapeutic recommendations 2026-01-26
    No abstract
    William H Frishman